Skip to main content

Table 3 mAbs authorized for the treatment of MS in the US (up until September 2022): administration routes, dosing regimens and product presentations (adult indications)

From: Customer-centric product presentations for monoclonal antibodies

mAb

Administration route and dosing regimena

IV product presentationsa

SC product presentationsa

IV

SC

Natalizumab

300 mg q4w

-b

300 mg/15 mL in single-dose vial

-b

Alemtuzumab

Initial treatment (2 courses):

First course of 12 mg/day on 5 consecutive days; second course of 12 mg/day on 3 consecutive days 12 months after first treatment course

Subsequent treatment courses:

12 mg/day on 3 consecutive days as needed, at least 12 months after the previous course

-

12 mg/1.2 mL in single-dose vial

-

Ocrelizumab

Start dose:

2*300 mg separated by two weeks

Subsequent doses:

600 mg q6m

-

300 mg/10 mL in single-dose vial

 

Ofatumumab

-

Initial dosing:

20 mg administered at

weeks 0, 1, and 2

Subsequent dosing:

20 mg q1m starting at week 4

-

20 mg/0.4 mL solution in single-dose prefilled pen or single-dose prefilled syringe

  1. IV intravenous, mg milligram, mL milliliter, qXd every X day, qXm every X month, qXw every X week, SC subcutaneous
  2. aThis table lists FDA-approved products; deviations with EMA-approved product presentations are indicated as a footnote
  3. bA SC formulation for natalizumab in MS is approved in the EU